Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 9 Lymphoma, Mantle-Cell 8 Breast Neoplasms 7 Lymphoma 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, T-Cell 5 Lymphoma, Non-Hodgkin 5 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, Follicular 5 Lymphoma, B-Cell, Marginal Zone 5 Lymphoma, B-Cell 5 Recurrence 4 Neuroblastoma 4 Myelodysplastic Syndromes 4 Mycosis Fungoides 4 Multiple Myeloma 4 Lymphoma, T-Cell, Cutaneous 4 Leukemia 4 Congenital Abnormalities 4 Carcinoma, Non-Small-Cell Lung 4 Brain Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Prostatic Neoplasms 3 Leukemia, Myelomonocytic, Acute 3 Leukemia, Monocytic, Acute 3 Leukemia, Megakaryoblastic, Acute 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia, Erythroblastic, Acute 3 Glioblastoma 3 Burkitt Lymphoma 3

Interventions

pembrolizumab 1 cixutumumab 1 Vorinostat 1 Temozolomide 1 Sunitinib 1 Oncolytic Virotherapy 1 Erlotinib Hydrochloride 1 Antibodies, Monoclonal 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroectodermal Tumors × Vorinostat × Clear all

NCT03561259 2023-02-16

OPTIMUM

Jubilant DraxImage Inc.

Phase 2 Unknown

Neoplasms, Neuroblastoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡